Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage :: In Vivo

Sep 20, 2023

Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. Brian Yang takes a deeper look into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations.

AstraZeneca and CANbridge obtain new approvals for their rare disease drugs in China, where a new domestic mRNA vaccine is also being made available amid a new wave of COVID infections. Meanwhile, the CEOs of pharma and other companies pay visits, showing China remains high on their list of global priorities.

Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. In this case study, Scrip takes a deep dive into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations.

China has taken a new counterstrike against the US in the chips sector, but the risk of potential wider impact on the biopharma sector appears to be limited given other tighter regulations already in place.

View full table

Your username does not meet the requirements.

Sorry - this email domain is not allowed.

Sorry - public email accounts are not allowed. Please provide a work email address.

An account with that username already exists.

Unfortunately we've not been able to process your registration. Please contact support.

Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. [email protected].

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

All set! This article has been sent to [email protected].

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please make sure all fields are completed.

Please enter a valid e-mail address

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Subject: Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage

Add a personalized message to your email

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Finish creating your saved search alert after you sign in